PT20 is a novel iron-based phosphate binder, that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD).
- PT20 is exclusively licensed from United Kingdom Research and Innovation (formerly the Medical Research Council) in the United Kingdom.
- Patents protect PT20 out to 2029. An additional five-year supplementary protection is expected to be granted upon approval in Europe, extending patent protection to 2034. The same is likely to apply in the US.
- PT20 has successfully completed one pivotal study and now requires one further pivotal study after which regulatory filings for marketing approval would be expected to follow.
PT30 and PT40
PT30 is a concept that is aimed at developing a hypo-allergenic IV iron therapy, whilst PT40 is being developed to be the first generic version of iron sucrose. Both assets are in preclinical development.